Literature DB >> 16174936

Use of propofol to control refractory involuntary movements.

David V Lardizabal1, Vivek Sabharwal, Ali Jahan, Samay Jain, Christopher Snyder, Marc J Popovich, Michael DeGeorgia.   

Abstract

The authors report the first case of propofol use for the control of non-epileptic involuntary movements in a patient with postviral encephalitis. The withdrawal from propofol was associated with re-emergence of involuntary movements. The patient was maintained on propofol infusion for 6 months while a series of medications were used in an attempt to control the movements. The movements were finally controlled with high doses of phenobarbital, diazepam, and olanzapine, and the propofol was slowly weaned.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 16174936     DOI: 10.1385/NCC:1:3:367

Source DB:  PubMed          Journal:  Neurocrit Care        ISSN: 1541-6933            Impact factor:   3.210


  13 in total

1.  Pharmacokinetics of propofol during and after long-term continuous infusion for maintenance of sedation in ICU patients.

Authors:  G R Bailie; I D Cockshott; E J Douglas; B J Bowles
Journal:  Br J Anaesth       Date:  1992-05       Impact factor: 9.166

2.  Changes of propofol concentration in cerebrospinal fluid during continuous infusion.

Authors:  Andrzej L Dawidowicz; Rafal Kalityński; Andrzej Nestorowicz; Anna Fijalkowska
Journal:  Anesth Analg       Date:  2002-11       Impact factor: 5.108

3.  Treatment of refractory status epilepticus with propofol: clinical and pharmacokinetic findings.

Authors:  M M Stecker; T H Kramer; E C Raps; R O'Meeghan; E Dulaney; D J Skaar
Journal:  Epilepsia       Date:  1998-01       Impact factor: 5.864

4.  Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes.

Authors:  M H Court; S X Duan; L M Hesse; K Venkatakrishnan; D J Greenblatt
Journal:  Anesthesiology       Date:  2001-01       Impact factor: 7.892

5.  Pharmacokinetics of long-term propofol infusion used for sedation in ICU patients.

Authors:  J Albanese; C Martin; B Lacarelle; P Saux; A Durand; F Gouin
Journal:  Anesthesiology       Date:  1990-08       Impact factor: 7.892

Review 6.  Propofol. An update of its use in anaesthesia and conscious sedation.

Authors:  H M Bryson; B R Fulton; D Faulds
Journal:  Drugs       Date:  1995-09       Impact factor: 9.546

Review 7.  Propofol. A review of its pharmacodynamic and pharmacokinetic properties and use as an intravenous anaesthetic.

Authors:  M S Langley; R C Heel
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

8.  Effects of propofol on human hepatic microsomal cytochrome P450 activities.

Authors:  D McKillop; M J Wild; C J Butters; C Simcock
Journal:  Xenobiotica       Date:  1998-09       Impact factor: 1.908

9.  Human cytochrome P450 mono-oxygenase system is suppressed by propofol.

Authors:  T L Chen; T H Ueng; S H Chen; P H Lee; S Z Fan; C C Liu
Journal:  Br J Anaesth       Date:  1995-05       Impact factor: 9.166

10.  Structural evidence that propofol stabilizes different GABA(A) receptor states at potentiating and activating concentrations.

Authors:  Daniel B Williams; Myles H Akabas
Journal:  J Neurosci       Date:  2002-09-01       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.